Egypt's Kahira Pharmaceuticals profit increases

The listed company posted a 31.6% YoY rise in its net profit in the first three months of the fiscal year 2019/2020

  
Pharmacists in Jordan-based Hikma Pharmaceuticals package generic versions of Ciprofloxacin hydrochloride 750 mg which will be exported to the U.S. and Western markets in Amman February 8, 2011. To go with Interview PHARMA-HIKMA/JORDAN REUTERS/Ali Jarekji (JORDAN - Tags: HEALTH BUSINESS) Image used for illustrative purpose

Pharmacists in Jordan-based Hikma Pharmaceuticals package generic versions of Ciprofloxacin hydrochloride 750 mg which will be exported to the U.S. and Western markets in Amman February 8, 2011. To go with Interview PHARMA-HIKMA/JORDAN REUTERS/Ali Jarekji (JORDAN - Tags: HEALTH BUSINESS) Image used for illustrative purpose

REUTERS/Ali Jarekji
 

Egypt - Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 12% Year on Year (YoY) increase in its net profit in the July-March period of 2012, according to the company’s unaudited financial statements filed to the Egyptian Exchange on May 5th.

The company achieved a net profit of EGP 102.932 million in the July-March period in 2021, compared to EGP 92.234 million in the prior-year period.

The listed company posted a 31.6% YoY rise in its net profit in the first three months of the fiscal year 2019/2020, recording EGP 33.85 million when compared to EGP 25.73 million achieved in the prior-year period.

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.

Copyright © 2021 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Equities